Bill Guyer

发表

Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens

B. Kearney, T. Hawkins, Wenoah Veikley, 2005, Journal of acquired immune deficiency syndromes.

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens

R. Haubrich, M. Das, D. Asmuth, 2020, PloS one.

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

U. Bredeek, E. Dejesus, H. Khanlou, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir‐experienced, NS5A treatment‐naïve patients: Findings from two randomized trials

R. Haubrich, Minhee Kang, P. Ghali, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Handling Editor: Janus Ong Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir- experienced, NS5A treatment-naive patients: findings from two randomized trials

R. Haubrich, Minhee Kang, P. Ghali, 2017 .

NS 5 A treatment-naive patients : findings from two randomized trials

R. Haubrich, Minhee Kang, P. Ghali, 2017 .

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b

K. White, M. Markowitz, H. Stellbrink, 2014, The Lancet. Infectious diseases.

Trends in HIV-1 Reverse Transcriptase Resistance-Associated Mutations and Antiretroviral Prescription Data from 2003–2010

C. Gibbs, M. Haddad, Bill Guyer, 2012, Antiviral therapy.

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

C. Farthing, Bill Guyer, H. Khanlou, 2005, AIDS patient care and STDs.

Serious Renal Impairment Occurs Rarely with Use of Tenofovir DF

James D. Scott, R. Bolan, Bill Guyer, 2006, HIV clinical trials.

Promotion-resistant JB6 mouse epidermal cells exhibit defects in phosphatidylethanolamine synthesis and phorbol ester-induced phosphatidylcholine hydrolysis.

Z. Dong, Z. Kiss, Bill Guyer, 1997, The Biochemical journal.

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

K. Aoki, K R Aoki, B Guyer, 2001, European journal of neurology.

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

M. Bloch, S. Hodder, Bill Guyer, 2013, HIV clinical trials.

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

K. White, C. Cohen, D. Wohl, 2012 .

The Long-Range Prognosis of Arachnoiditis

L. Wiltse, Bill Guyer, M. L. Eskay, 1989, Spine.

Computed tomography of calcaneal fractures: anatomy, pathology, dosimetry, and clinical relevance.

B. Fredrickson, E. Levinsohn, Bill Guyer, 1985, AJR. American journal of roentgenology.

Comprehensive experience on intraplaque hemorrhage of the carotid artery

C. Hodge, R. Schwartz, A. Culebras, 1991 .

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.

C. Farthing, Bill Guyer, H. Khanlou, 2005, Journal of acquired immune deficiency syndromes.